Steve Corder, MD
Psychiatry · Wheeling, WVNPI 1184726804
Payments from drug & device makers
Across 774 payments — averaging $73.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$45K
- AbbVie$2K
- Vanda Pharmaceuticals Inc.$2K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Johnson & Johnson$1K
- plus $4K from 15 others
What the payments were for
- Consulting fees$3,1305%
- Speaking & faculty fees$35,54962%
- Travel & lodging$2,7345%
- Food & beverage$15,17027%
- Education$6181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 166 | $45,378 |
| AbbVie(2 entities) | 107 | $1,945 |
| Vanda Pharmaceuticals Inc. | 85 | $1,580 |
| Alkermes, Inc. | 80 | $1,558 |
| Neurocrine Biosciences, Inc. | 80 | $1,505 |
| Johnson & Johnson | 53 | $1,009 |
| Otsuka America Pharmaceutical, Inc. | 41 | $957 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 45 | $836 |
| Indivior Inc. | 24 | $472 |
| Sunovion Pharmaceuticals Inc. | 32 | $421 |
| Janssen Scientific Affairs, LLC | 2 | $400 |
| Lundbeck LLC | 17 | $302 |
| E.r. Squibb & Sons, L.L.C. | 13 | $265 |
| Axsome Therapeutics, Inc. | 4 | $169 |
| Avanir Pharmaceuticals, Inc. | 8 | $137 |
| Noven Therapeutics, LLC | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $81 |
| Merck | 3 | $40 |
| Braeburn Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Sage Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,201 in reported general payments places this provider in the 90th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 19 | $144,242 |
| IngrezzaValbenazine Tosylate | 15 | $119,187 |
| Invega SustennaPaliperidone Palmitate | 25 | $89,166 |
| VraylarCariprazine Hcl | 43 | $51,410 |
| AristadaAripiprazole Lauroxil | 15 | $46,622 |
| Clozapine | 474 | $41,474 |
| FanaptIloperidone | 16 | $40,665 |
| EmsamSelegiline | 14 | $28,001 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $22,710 |
| Risperidone ErRisperidone Microspheres | 13 | $18,647 |
| CaplytaLumateperone Tosylate | 12 | $17,157 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 160 | $12,275 |
| ExelonRivastigmine | 12 | $8,097 |
| Paliperidone ErPaliperidone | 35 | $7,429 |
| Divalproex Sodium ErDivalproex Sodium | 139 | $6,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $45,378 | $144,24219 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,505 | $119,18715 claims |
| Johnson & JohnsonInvega Sustenna | $1,009 | $89,16625 claims |
| AbbVieVraylar, Fetzima | $1,945 | $58,07756 claims |
| Alkermes, Inc.Aristada | $1,558 | $46,62215 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,580 | $40,66516 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $137 | $22,71014 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $836 | $17,15712 claims |
| Indivior Inc.Suboxone | $472 | $5,79526 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $81 | $4,35712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Wheeling
- Ryan WakimWheeling$772K
- Alfredo AguirreWheeling$2K
- Paul PapadimitriouWheeling$832
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Daniel ThistlethwaiteSouth Charleston$468K
- Walter ByrdMorgantown$299K
- Fahd MousaCharleston$200K
- Debra StultzBarboursville$176K
- Shahnoor KhanMartinsburg$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.